



GOLD NANOPARTICLE-MEDIATED PLASMONIC BLOCK COPOLYMERS: DESIGN, SYNTHESIS, AND APPLICATIONS IN SMART DRUG DELIVERY

Dipongkar Ray Sobuj¹; Tamanna Rashid²; Saiful Islam Arif³; Shraboni Ghosh⁴;

- [1]. Master of Science in Chemistry, Lamar University, Texas, USA;
Email: raydipongkar@gmail.com
- [2]. Master of Science in Chemistry, Lamar University, Texas, USA;
Email: trshormi@gmail.com
- [3]. MBBS, Jahirul Islam Medical College, Dhaka, Bangladesh;
Email: saifulw07@gmail.com
- [4]. Bachelor of Science in Chemistry, Government City College, Chattogram, Bangladesh;
Email: shrabonighoshshanta@gmail.com

ABSTRACT

The development of advanced drug delivery systems has become a central focus in biomedical engineering and pharmaceutical sciences, particularly with the integration of nanotechnology into polymeric platforms. In this study, we present the design, synthesis, and application of an asymmetric diblock copolymer mediated by plasmonic gold nanoparticles for controlled and stimuli-responsive drug delivery. The system leverages the unique physicochemical properties of gold nanoparticles, including surface plasmon resonance, biocompatibility, and tunable optical activity, in conjunction with the self-assembly behavior of amphiphilic block copolymers. The copolymer is composed of hydrophilic and hydrophobic segments, strategically engineered to facilitate micelle formation in aqueous environments, where the hydrophobic core serves as a reservoir for poorly soluble therapeutic molecules. The incorporation of plasmonic gold nanoparticles into the polymer backbone introduces multifunctional responsiveness to external stimuli. Specifically, near-infrared (NIR) light irradiation induces localized heating via plasmonic resonance, resulting in the destabilization and disruption of the micellar architecture. This process enables the controlled release of hydrophobic drugs encapsulated in the micelle interior. The synthetic design of the diblock copolymer was optimized to balance stability in circulation with responsiveness upon exposure to external triggers. Structural characterization confirmed successful conjugation of the polymeric segments with gold nanoparticles, while self-assembly studies revealed stable micelle formation under physiological conditions. Drug encapsulation efficiency was evaluated using hydrophobic model compounds, and release kinetics demonstrated significant responsiveness to NIR irradiation, confirming the role of plasmonic resonance in micelle destabilization. Preliminary cytocompatibility studies suggest that the hybrid system maintains biocompatibility, underscoring its potential in translational applications. The findings lay the groundwork for further exploration of plasmonic block copolymers in areas such as targeted cancer therapy, photothermal treatment, and multimodal therapeutic strategies. Future investigations may focus on in vivo pharmacokinetics, biodistribution, and therapeutic efficacy to validate the clinical potential of this system.

KEYWORDS

Gold Nanoparticles; Plasmonic Block Copolymers; Stimuli-Responsive Drug Delivery; Near-Infrared (NIR) Triggered Release; Self-Assembled Polymeric Micelles.

Citation:

Sobuj, D. R., Rashid, T., Arif, S. I. & Ghosh, S., (2024). Gold nanoparticle-mediated plasmonic block copolymers: Design, synthesis, and applications in smart drug delivery. *American Journal of Scholarly Research and Innovation*, 3(2), 80 - 98. <https://doi.org/10.63125/pgk8tt08>

Received:

August 28, 2024

Revised:

September 17, 2024

Accepted:

October 26, 2024

Published:

November 11, 2024




Copyright:

© 2024 by the author. This article is published under the license of American Scholarly Publishing Group Inc and is

INTRODUCTION

Drug delivery refers to the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals, and modern drug delivery systems aim not only to transport active agents but also to control their release, stability, and bioavailability in a precise and efficient manner (Allen & Cullis, 2013; Langer, 1990). Among the different nanoscale carriers developed, micelles derived from amphiphilic block copolymers have gained considerable recognition due to their unique structural characteristics and ability to encapsulate hydrophobic drugs within their self-assembled hydrophobic cores (Kataoka et al., 2001; Torchilin, 2001). Amphiphilic block copolymers consist of hydrophilic and hydrophobic segments, which spontaneously assemble in aqueous environments into core-shell micelles, where the hydrophobic domain functions as a reservoir for poorly soluble drugs and the hydrophilic part provides colloidal stability and biocompatibility (Kim et al., 2010; Gaucher et al., 2005). This dual structural organization allows polymeric micelles to improve water solubility of hydrophobic drugs, extend systemic circulation times, and facilitate preferential accumulation in pathological tissues. Their size range, typically 10–100 nm, makes them suitable for passive targeting via the enhanced permeability and retention (EPR) effect, particularly in solid tumors where vascular permeability is increased (Maeda et al., 2000; Matsumura & Maeda, 1986). From a therapeutic perspective, these structural and functional attributes place polymeric micelles among the most promising nanocarrier platforms for controlled drug delivery.


Figure 1: Plasmonic Block Copolymer Micelles for NIR-Triggered Drug Delivery



Globally, nanotechnology has revolutionized the pharmaceutical and biomedical sectors, with nanocarrier-based drug delivery systems playing a transformative role in cancer therapy, chronic disease management, and advanced therapeutics (Davis et al., 2008; Peer et al., 2007). In oncology alone, the development of nanoscale drug carriers has been instrumental in enhancing the therapeutic index of cytotoxic drugs by enabling higher drug concentrations at tumor sites while lowering systemic toxicity (Duncan & Gaspar, 2011; Zhang et al., 2012). Polymeric micelles, in particular, have received regulatory approvals and clinical attention, such as Genexol-PM® (a paclitaxel-loaded polymeric micelle) that is marketed in several countries for breast and non-small-cell lung cancers (Kim et al., 2004; Koizumi et al., 2000). This underscores their global impact on

healthcare delivery and their relevance across continents, including North America, Asia, and Europe. The adaptability of micellar carriers to encapsulate diverse drugs and their modifiability with ligands for active targeting contribute to their wide adoption in translational research (Kwon, 2003; Yokoyama, 2014). Additionally, the international pharmaceutical market increasingly invests in smart nanocarriers that are responsive to physiological or external stimuli, reflecting a worldwide consensus on their potential to address unmet clinical challenges (Farokhzad & Langer, 2009; Mura et al., 2013). Thus, the field of block copolymer micelles represents not only a cutting-edge scientific frontier but also a globally significant strategy in the advancement of precision medicine.

Figure 2: Stimuli-Responsive Block Copolymer Micelles for Controlled Drug Delivery



The concept of stimuli-responsive drug delivery systems refers to carriers engineered to release therapeutic agents upon exposure to internal or external triggers, thereby providing spatial and temporal control over drug release (Ravi Kumar et al., 2001; Qiu & Park, 2001). Internal stimuli include physiological factors such as pH, enzymatic activity, and redox potential, while external stimuli include temperature, magnetic fields, ultrasound, and light (Stella & He, 2008; Aluri et al., 2009). Block copolymer micelles are particularly suitable for stimuli-responsiveness due to their amphiphilic design and ease of chemical modification (Bae et al., 2005; Chen & Liu, 2016). For instance, thermoresponsive micelles can undergo sol-gel transitions under physiological conditions, while pH-sensitive micelles destabilize in acidic environments, such as those found in tumor microenvironments (Kost, 1995; Rapoport, 2007). Among these, light-responsive micelles are of growing interest because they offer non-invasive, spatiotemporally controlled drug release, which can be precisely tuned by adjusting light wavelength, intensity, and duration (Shen et al., 2013; Yao et al., 2016). Such systems enable on-demand drug release at specific sites of interest, reducing systemic side effects and enhancing therapeutic outcomes. The wide range of stimuli employed in polymeric micelle design demonstrates the versatility of these nanocarriers and their potential to meet diverse clinical requirements across therapeutic fields. Despite the advantages of light-responsive systems, most early designs have relied on ultraviolet (UV) or visible light to trigger drug release, which poses limitations for biological applications (Sortino, 2012; Zhao et al., 2012). UV light, while effective in cleaving light-sensitive bonds within polymeric backbones, suffers from poor tissue penetration, high scattering, and potential cytotoxicity due to its high energy, which can damage healthy tissues and cellular DNA (Shen et al., 2008; Weissleder, 2001). Similarly, visible light offers improved penetration relative to UV but remains limited in depth and may still lead to off-target phototoxic effects (Fomina et al., 2010; Kwon et al., 2013). These constraints have driven researchers toward alternative wavelengths, particularly near-infrared (NIR) light, which offers superior penetration depth (up to

several centimeters in tissues) and significantly reduced phototoxicity (Yao et al., 2009; Smith et al., 2009). The so-called "optical window" of NIR light, ranging from 700 to 1,100 nm, allows for minimal interference from water and hemoglobin absorption, making it especially suitable for in vivo biomedical applications (Vollmer & Arnold, 2008; Weissleder, 2001). Therefore, developing block copolymer micelles that respond to NIR light has become a crucial step in advancing light-mediated drug delivery systems beyond laboratory feasibility into clinically viable strategies.

The primary objective of this study is to design, synthesize, and evaluate a novel class of gold nanoparticle-mediated plasmonic diblock copolymers for application in smart drug delivery. The research is directed toward addressing critical challenges associated with conventional chemotherapy, particularly poor solubility of hydrophobic drugs, lack of site-specific targeting, uncontrolled drug release, and systemic toxicity. By integrating amphiphilic diblock copolymers with plasmonic gold nanoparticles, this work aims to create a hybrid system that combines the benefits of polymeric micelles with the unique photothermal responsiveness of gold nanomaterials. The specific objective is to engineer a self-assembling micellar system in which the hydrophobic domain serves as a reservoir for hydrophobic drugs while the hydrophilic shell ensures solubility, circulation stability, and biocompatibility in physiological environments. Upon exposure to near-infrared light, gold nanoparticles incorporated within the polymeric matrix will generate localized heat through surface plasmon resonance, inducing destabilization of the micellar architecture and triggering the release of encapsulated drug molecules. This controllable release mechanism is designed to provide spatial and temporal precision in therapeutic delivery, enabling selective drug release at tumor sites while minimizing damage to healthy tissues. The study also seeks to systematically investigate the physicochemical characteristics of the synthesized plasmonic copolymer micelles, including their stability, morphology, phase transformation behavior, and drug encapsulation efficiency. A key objective is to demonstrate the controlled release profile of hydrophobic anticancer agents under near-infrared light stimulation, thereby confirming the functional role of plasmonic gold nanoparticles in enabling external stimulus-responsiveness. Furthermore, biological evaluation will be undertaken to validate the efficacy of these nanocarriers in cancer models, specifically breast cancer cell lines such as MDA-MB-231 and T-47D, as well as lung cancer cell line A549. The overarching objective is to highlight the capacity of gold nanoparticle-mediated diblock copolymer micelles to serve as smart nanoplatforms for precise, efficient, and minimally invasive drug delivery. Through this work, the study aims to contribute to the advancement of nanomedicine by presenting a rationally designed hybrid system that bridges polymer science and plasmonic nanotechnology for therapeutic innovation.

LITERATURE REVIEW

The scientific exploration of nanocarriers for drug delivery has evolved significantly over the past three decades, with block copolymer micelles and gold nanoparticles emerging as two of the most promising platforms in nanomedicine. Polymeric micelles constructed from amphiphilic block copolymers offer a versatile system for encapsulating hydrophobic drugs, improving aqueous solubility, prolonging systemic circulation, and enabling passive targeting through the enhanced permeability and retention effect. Concurrently, gold nanoparticles have attracted considerable attention due to their unique optical and plasmonic properties, high surface functionalization potential, and excellent biocompatibility. Together, these two systems have converged into a hybrid class of nanocarriers that combine the structural advantages of polymeric micelles with the photothermal responsiveness of plasmonic nanomaterials. This integration has led to the development of stimuli-responsive drug delivery systems capable of precise spatiotemporal drug release, particularly when triggered by near-infrared light, which penetrates deeply into biological tissues and minimizes collateral damage to surrounding cells.


An analysis of the existing literature reveals that researchers have approached this field through multiple perspectives, ranging from fundamental studies on polymer self-assembly and micellar stability, to engineering gold nanoparticles with controlled size and shape for maximal plasmonic efficiency, to investigating biological outcomes in in vitro and in vivo models. The literature further demonstrates that the transition from UV- or visible-light responsive micelles to near-infrared-sensitive plasmonic systems marks a pivotal advancement in biomedical nanotechnology. In addition, prior work has explored encapsulation of hydrophobic anticancer drugs, conjugation with targeting ligands, and multimodal therapeutic applications such as photothermal and chemo-phototherapy. By examining these interrelated bodies of research, the present literature review aims to critically

evaluate the design, synthesis, and biomedical applications of gold nanoparticle-mediated block copolymer micelles. The following outline provides a systematic framework for reviewing the literature, emphasizing specific dimensions of scientific progress and research focus within this multidisciplinary domain.

Nanocarrier Systems in Drug Delivery

The evolution of nanoscale carriers in pharmaceutical sciences reflects a paradigm shift in drug delivery, where the focus has moved from passive administration to active, controlled, and targeted systems. Early efforts in drug delivery primarily centered on improving solubility and bioavailability of poorly soluble drugs through simple formulations, but the emergence of nanoscale materials introduced entirely new possibilities for therapeutic precision (Allen & Cullis, 2013; Langer, 1990). Liposomes were among the first nanoscale carriers to achieve clinical recognition, with Doxil® marking a milestone in nanomedicine by reducing systemic toxicity while maintaining efficacy in cancer therapy (Barenholz, 2012; Allen & Cullis, 2013). Building on this foundation, polymeric nanoparticles and micelles were developed, enabling encapsulation of hydrophobic drugs and offering improved pharmacokinetics and circulation stability (Torchilin, 2007; Kataoka et al., 2001). Research on dendrimers, polymer-drug conjugates, and inorganic nanoparticles further expanded the diversity of nanocarriers, establishing a multi-platform approach to therapeutic design (Boas & Heegaard, 2004; Duncan, 2006). Over time, attention has shifted to stimuli-responsive nanocarriers that release drugs under specific physiological or external conditions, reflecting a progression from static carriers to dynamic, "smart" systems (Mura et al., 2013; Bae et al., 2005). The incorporation of targeting ligands and surface modifications has also advanced the field, enabling carriers to recognize diseased tissues or specific cell receptors (Kwon, 2003; Peer et al., 2007). Collectively, these developments mark the transformation of nanocarrier science into a central pillar of modern pharmaceutical innovation, reshaping therapeutic strategies across oncology, infectious diseases, and chronic conditions (Zhang et al., 2012; Shi et al., 2017).

Figure 3: Nanocarrier Systems in Drug Delivery: Structures and Global Therapeutic Applications




Nanocarriers confer significant advantages over conventional drug delivery systems by addressing key limitations of solubility, stability, biodistribution, and specificity. Traditional formulations often face challenges in delivering hydrophobic drugs due to poor aqueous solubility, leading to low bioavailability and erratic pharmacokinetics (Lipinski, 2000; Loftsson & Brewster, 2012). Nanocarriers overcome these issues by encapsulating hydrophobic compounds within their cores, significantly enhancing solubility and dissolution rates (Gaucher et al., 2005; Kim et al., 2010). Moreover, their nanoscale size allows for extended systemic circulation, reduced clearance by the

reticuloendothelial system, and favorable biodistribution patterns (Cabral et al., 2011; Allen & Cullis, 2013). Another advantage is the ability of nanocarriers to exploit the enhanced permeability and retention (EPR) effect, enabling preferential accumulation in tumor tissues compared to conventional free drugs (Matsumura & Maeda, 1986; Maeda et al., 2000). Functional modifications further expand their utility by allowing active targeting via conjugation with antibodies, peptides, or small molecules that recognize tumor-specific receptors, thereby improving therapeutic index (Peer et al., 2007; Davis et al., 2008). Importantly, nanocarriers can be engineered for controlled release, ensuring sustained drug availability at the site of action while minimizing systemic toxicity (Torchilin, 2007; Rapoport, 2007). Conventional systems often require frequent dosing and are associated with off-target effects, whereas nanocarrier formulations improve patient compliance and safety by reducing dosing frequency and adverse effects (Duncan & Gaspar, 2011; Shi et al., 2017). These combined features illustrate why nanocarriers are increasingly considered superior to traditional formulations, offering multifaceted benefits that span pharmacological performance, clinical outcomes, and patient-centered care.

Amphiphilic Block Copolymers

Amphiphilic diblock copolymers are macromolecules composed of two chemically distinct polymer blocks, one hydrophobic and the other hydrophilic, covalently linked to form a single chain. This structural duality underlies their ability to spontaneously self-assemble into micellar nanostructures in aqueous media, making them attractive platforms for drug delivery. The hydrophobic block commonly comprises synthetic polymers such as poly(ϵ -caprolactone), polylactic acid, or polystyrene, while the hydrophilic block often consists of polyethylene glycol (PEG) or poly(N-vinylpyrrolidone), conferring water solubility and stealth characteristics (Kataoka et al., 2001; Torchilin, 2001). The amphiphilic balance between the blocks determines the critical micelle concentration (CMC), stability, and morphology of the resulting micelles (Bae et al., 2005; Gaucher et al., 2005). Studies have shown that tuning block lengths and compositions enables control over micellar size, aggregation number, and core-shell ratios, which directly influence drug loading capacity and release kinetics (Kwon, 2003; Nishiyama & Kataoka, 2006). Structural versatility also extends to stimuli-sensitive modifications, where functional groups responsive to pH, temperature, or light are integrated into the copolymer backbone (Mura et al., 2013; Rapoport, 2007). Moreover, the chemical design of amphiphilic copolymers facilitates their conjugation with targeting ligands such as antibodies or peptides, creating micelles capable of active targeting in cancer therapy (Davis et al., 2008; Peer et al., 2007). Collectively, the structural principles of amphiphilic diblock copolymers provide a rational framework for engineering multifunctional nanocarriers tailored to therapeutic requirements, with extensive literature underscoring their versatility in biomedical applications (Allen & Cullis, 2013; Kim et al., 2010; Shi et al., 2017).

Figure 4: Amphiphilic Block Copolymer Micelles: Structure, Self-Assembly, and Drug Encapsulation




The mechanism of micelle formation by amphiphilic diblock copolymers in aqueous environments is driven by the minimization of free energy through hydrophobic and hydrophilic interactions. Upon reaching the critical micelle concentration, the hydrophobic blocks aggregate to form a compact core, while the hydrophilic blocks extend into the surrounding medium, forming a corona that stabilizes the micelle (Kataoka et al., 2001; Torchilin, 2007). This self-assembly process is thermodynamically favorable, as it reduces unfavorable interactions between hydrophobic segments and water while maximizing entropy of the solvent (Gaucher et al., 2005; Bae et al., 2005). The resulting nanostructures typically range from 10 to 100 nm, a size suitable for systemic circulation and passive tumor targeting via the enhanced permeability and retention effect (Maeda et al., 2000; Matsumura & Maeda, 1986). Studies using dynamic light scattering, transmission electron microscopy, and small-angle neutron scattering have confirmed the structural stability and spherical morphology of polymeric micelles under physiological conditions (Cabral et al., 2011; Nishiyama & Kataoka, 2006). Variations in block length, solvent polarity, and ionic strength significantly influence micellization behavior, allowing fine-tuning of size and stability (Kim et al., 2010; Harada & Kataoka, 1999). Importantly, micelle formation is reversible; dilution below the CMC or destabilization under stimuli can lead to disassembly and release of encapsulated agents (Shen et al., 2013; Mura et al., 2013). This dynamic nature provides opportunities to engineer micelles with responsive release mechanisms for site-specific therapy. Thus, the mechanisms underlying micelle formation illustrate how simple molecular architecture translates into complex nanoscale organization, enabling reproducible and controllable nanocarrier systems for biomedical use (Torchilin, 2001; Shi et al., 2017). Drug encapsulation is a defining feature of amphiphilic block copolymer micelles, primarily facilitated by the hydrophobic core, which acts as a reservoir for poorly water-soluble drugs. Hydrophobic interactions between drug molecules and the core polymer segment stabilize encapsulated compounds, significantly enhancing aqueous solubility and bioavailability (Kwon, 2003; Gaucher et al., 2005). Hydrophobic anticancer agents such as paclitaxel, doxorubicin, and camptothecin have been successfully incorporated into polymeric micelles, with studies reporting improved solubilization compared to free drugs (Kim et al., 2004; Cabral et al., 2011). Encapsulation efficiency is influenced by block composition, drug-polymer compatibility, and preparation methods, such as solvent evaporation or dialysis (Bae et al., 2005; Nishiyama & Kataoka, 2006). Polymeric micelles also provide protection against premature degradation and clearance, extending circulation time in vivo (Torchilin, 2007; Duncan & Gaspar, 2011). Furthermore, the micellar corona, often composed of PEG, reduces protein adsorption and opsonization, allowing for prolonged half-life and reduced immunogenicity (Allen & Cullis, 2013; Cabral et al., 2011). Importantly, encapsulated drugs retain their pharmacological activity, and release can be modulated by micelle composition or external stimuli, ensuring controlled therapeutic delivery (Rapoport, 2007; Mura et al., 2013). Encapsulation also mitigates systemic toxicity by reducing off-target exposure, as demonstrated in clinical formulations like Genexol-PM®, a paclitaxel-loaded micelle approved for cancer therapy (Kim et al., 2004; Koizumi et al., 2000). Collectively, the literature demonstrates that polymeric micelles are effective vehicles for encapsulating hydrophobic drugs, offering substantial advantages over conventional delivery approaches (Zhang et al., 2012; Shi et al., 2017).

Micelle preparation

The preparation of micellar solutions from amphiphilic diblock copolymers has been widely studied, as their self-assembly in selective solvents yields nanostructures capable of encapsulating hydrophobic therapeutics and serving as platforms for further functionalization with plasmonic materials. The most common preparation routes include direct dissolution, solvent evaporation, dialysis, and nanoprecipitation, each exploiting solubility contrasts between hydrophilic and hydrophobic blocks (Kataoka et al., 2001; Torchilin, 2007). In direct dissolution, amphiphilic polymers dissolve in aqueous media above the critical micelle concentration (CMC), where hydrophobic blocks form the micellar core and hydrophilic blocks form the corona (Kim et al., 2010; Gaucher et al., 2005). Solvent evaporation methods involve dissolving diblock copolymers and hydrophobic cargo in volatile organic solvents, followed by evaporation and rehydration, producing well-defined micelles with high loading capacity (Bae et al., 2005; Nishiyama & Kataoka, 2006). Dialysis, one of the most frequently employed techniques, relies on gradual exchange of organic solvents with water through semi-permeable membranes, yielding stable micelles with narrow size distributions (Jones & Leroux, 1999; Wu et al., 2015). Nanoprecipitation, by contrast, rapidly mixes polymer solutions in

miscible solvents with a non-solvent, triggering instant self-assembly into nanoscale micelles (Liu et al., 2011; Harada & Kataoka, 1999). Micelle preparation is strongly influenced by solvent polarity, polymer block length, and hydrophilic–lipophilic balance, all of which dictate micelle size, stability, and encapsulation efficiency (Matsumura & Maeda, 1986; Cabral et al., 2011). For biomedical applications, techniques that minimize harsh solvents are preferred to preserve therapeutic activity and ensure biocompatibility (Allen & Cullis, 2013; Duncan & Gaspar, 2011). Importantly, once micelles are prepared, they can be conjugated with plasmonic gold nanoparticles (AuNPs) to generate hybrid systems responsive to near-infrared (NIR) irradiation. Strategies include in situ reduction of gold precursors within micellar cores, electrostatic adsorption onto charged coronas, or thiol-mediated covalent anchoring to AuNPs (Jiang et al., 2008; Ghosh et al., 2008; Chen et al., 2010). Such hybrid micelles maintain stability while acquiring plasmonic responsiveness, enabling light-triggered drug release for targeted cancer therapy (Huang et al., 2007; Dreaden et al., 2012). Collectively, the literature demonstrates that diverse micelle preparation methods offer flexible routes for generating stable diblock copolymer micelles, which can then be integrated with gold nanomaterials to yield multifunctional nanocarriers optimized for biomedical use.

Figure 5: Methods of Micelle Preparation and Integration with Plasmonic Gold Nanoparticles




Artificial set up and NIR light exposure

Bench-scale evaluation of NIR-triggered release from plasmonic block-copolymer micelles typically combines a controlled optical train with solution assemblies whose composition, geometry, and temperature are tightly regulated. Micelles are prepared in selective solvent (e.g., buffered saline) and transferred to quartz cuvettes or jacketed glass reaction cells fitted with magnetic stirring to minimize thermal gradients, while concentration is kept above the critical micelle concentration to preserve core-shell organization (Kataoka et al., 2001; Gaucher et al., 2005; Torchilin, 2007). A continuous-wave 808–1064 nm diode or fiber laser—aligned through beam expanders and neutral-density filters—irradiates samples at calibrated power densities measured by a thermopile or photodiode power meter, with homogeneous spot sizes larger than the meniscus to avoid edge heating (Weissleder, 2001; Huang et al., 2007; Jain et al., 2006; Baffou & Quidant, 2013). Gold nanoparticles embedded in the micellar core or tethered to the polymer furnish strong NIR absorption via localized surface plasmon resonance, converting photon energy to heat within nanometers of the particle surface (Daniel & Astruc, 2004; Kelly et al., 2003; Eustis & El-Sayed, 2006). Local and bulk temperatures are tracked with fiber-optic microthermometry and infrared thermography to distinguish nanoscale photothermal events from bath heating, an important control because release profiles correlate with both local dissipation and macroscopic temperature rise (Baffou & Quidant, 2013; Huang & El-Sayed, 2010). Drug release is quantified by dialysis-sampling with HPLC/UV–Vis or fluorescence dequenching probes such as Nile Red or doxorubicin, while dynamic light scattering and ζ -potential assess micelle integrity during and after exposure (Gaucher et al., 2005; Cabral et al., 2011; Kim et al., 2010). Negative controls include non-plasmonic micelles and dark conditions; positive controls include bulk heating to matched temperatures to parse photothermal from purely thermal effects (Jiang et al., 2008; Chen et al., 2010; Dreaden et al., 2012). Together, these practices—optical calibration, thermal accounting, solution stability metrics, and orthogonal analytics—define an artificial set-up that reliably links NIR irradiation to micelle

destabilization and quantifiable payload liberation under physiochemically relevant conditions (Mura et al., 2013; Qiu & Park, 2001; Shi et al., 2017).

Upon NIR exposure, the plasmonic core transduces light into heat, raising local temperatures rapidly and weakening hydrophobic–hydrophilic segregation within the amphiphilic diblock, which manifests as core swelling, corona collapse, or full micelle disassembly depending on formulation and power density (Huang et al., 2007; Jain et al., 2012; Kim et al., 2011). Photothermal destabilization is amplified when thermo-responsive segments are present, because localized heating drives chain transitions across LCST-like thresholds and accelerates diffusion of entrapped molecules (Qiu & Park, 2001; Gil et al., 2012; Mura et al., 2013). Spectroscopic tracking during irradiation shows red-shifts or damping of the gold plasmon band when micelles reorganize or nanoparticles couple, while concurrent increases in drug absorbance/fluorescence in the release medium indicate payload escape (Kelly et al., 2003; Chen et al., 2010; Jiang et al., 2008). Time-resolved DLS and cryo-TEM corroborate structural pathways—core loosening, aggregation, or fragmentation—whereas calorimetry and thermal probes quantify dose-dependent heating that maps onto release rates (Baffou & Quidant, 2013; Cabral et al., 2011; Wu et al., 2015). Kinetic fitting commonly applies Higuchi or Korsmeyer–Peppas frameworks for diffusion/relaxation control, or biphasic models capturing an initial burst from shell perturbation followed by slower diffusion through reconfigured cores (Siepmann & Peppas, 2011; Bae et al., 2005; Gaucher et al., 2005). Parametric studies reveal that nanoparticle geometry (rods, shells, stars), loading fraction, and laser fluence govern both the magnitude and speed of release, with anisotropic Au structures shifting resonance into the biological window and improving photothermal efficiency (Nikoobakht & El-Sayed, 2003; Oldenburg et al., 1998; Dreaden et al., 2012). Biological relevance is established by coupling the optical assay with cell-level tests, where NIR-activated formulations increase intracellular drug accumulation and cytotoxicity relative to dark controls while maintaining colloidal stability in serum (Huang et al., 2007; Pissuwan et al., 2006; Shi et al., 2017; Peer et al., 2007). Across reports, concordant optical, thermal, and kinetic readouts substantiate a causal sequence: NIR absorption by AuNPs → localized heating → micelle destabilization → controlled liberation of hydrophobic therapeutics (Weissleder, 2001; Daniel & Astruc, 2004; Chen et al., 2010).

Figure 6: NIR Laser-Triggered Destabilization of Block Copolymer Micelles and Subsequent Drug Release



Characterization

Characterizing block copolymer (BCP) micelles integrated with plasmonic nanoparticles requires a combination of imaging, scattering, and spectroscopic techniques to validate their morphology, stability, and responsiveness to stimuli. Transmission electron microscopy (TEM) is frequently employed to directly visualize the nanoscale structure of micelles, providing high-resolution images of core–shell morphology and nanoparticle distribution within the micellar matrix (Cabral et al., 2011; Wu et al.,

2015). Dynamic light scattering (DLS) complements TEM by offering ensemble measurements of hydrodynamic size, polydispersity, and aggregation state in solution, capturing micelle stability before and after external triggers such as near-infrared (NIR) irradiation (Kim et al., 2010; Gao et al., 2014). DLS has been widely used to confirm micellar destabilization under photothermal conditions, as plasmonic heating induces measurable increases in particle size and dispersity (Huang et al., 2007; Jiang et al., 2008). In parallel, UV–Vis spectroscopy tracks changes in the surface plasmon resonance (SPR) band of gold nanoparticles, with shifts or broadening indicating micellar disruption or nanoparticle coupling (Kelly et al., 2003; Daniel & Astruc, 2004). Fluorescent dyes such as Nile Red or doxorubicin are often encapsulated as reporters, enabling spectroscopic quantification of release upon micelle destabilization (Chen et al., 2010; Dreaden et al., 2012). Together, TEM, DLS, and optical spectroscopy provide orthogonal confirmation of micellar structure, stability, and NIR-triggered release dynamics, ensuring accurate evaluation of these nanocarriers' functional performance (Torchilin, 2007; Mura et al., 2013; Shi et al., 2017). Beyond morphology, detailed physicochemical and thermal characterization is essential for validating the synthesis and functional properties of diblock copolymers. Nuclear magnetic resonance (NMR) spectroscopy is a key tool for determining monomer conversion, end-group fidelity, and block composition, offering molecular-level confirmation of successful polymerization (Moad et al., 2009; Perrier, 2017; Boyer et al., 2009). Gel permeation chromatography (GPC) provides complementary data on molecular weight distribution and dispersity, which are critical parameters influencing micelle size, stability, and drug-loading capacity (Matyjaszewski & Tsarevsky, 2009; Chiefari et al., 1998; Nishiyama & Kataoka, 2006). Differential scanning calorimetry (DSC) and differential thermal analysis are frequently employed to evaluate polymer thermal transitions such as glass transition temperature (T_g) and melting points, which directly impact micelle stability and responsiveness under physiological or photothermal conditions (Gil et al., 2012; Rapoport, 2007). Laser light scattering spectroscopy and small-angle X-ray scattering (SAXS) further probe micellar internal structures and provide insights into aggregation numbers and core dimensions (Jones & Leroux, 1999; Bae et al., 2005; Harada & Kataoka, 1999). Together, these methods yield a comprehensive profile of polymer composition, micelle stability, and thermoresponsive behavior. For plasmonic hybrids, characterization must also include optical techniques such as UV–Vis–NIR spectroscopy to confirm nanoparticle incorporation and localized surface plasmon resonance properties (Huang et al., 2007; Jain et al., 2006; Eustis & El-Sayed, 2006). This integrated suite of analytical tools ensures that BCP micelles are structurally verified, compositionally accurate, and functionally responsive to NIR light, thereby validating their use as advanced nanocarriers for drug delivery applications (Allen & Cullis, 2013; Zhang et al., 2012; Peer et al., 2007).


Study of the drugs

Literature describing benchtop monitoring of drug release from plasmonic block-copolymer micelles converges on cuvette-based optical set-ups that pair controlled near-infrared (NIR) irradiation with orthogonal analytical readouts. Amphiphilic diblock micelles are prepared above the critical micelle concentration, transferred to quartz cells, and irradiated with 808–1064 nm continuous-wave lasers whose power density and spot size are calibrated to avoid bulk overheating while exciting the localized surface plasmon resonance of embedded gold nanoparticles (Kelly et al., 2003; Daniel & Astruc, 2004; Weissleder, 2001; Huang et al., 2007; Jain et al., 2006). Photothermal conversion induces local heating and micelle destabilization, which is tracked by dynamic light scattering for hydrodynamic size and polydispersity, revealing core swelling or fragmentation during exposure (Gaucher et al., 2005; Kim et al., 2010; Cabral et al., 2011). UV–Vis–NIR spectroscopy simultaneously monitors the plasmon band for peak shifts/broadening indicative of nanoparticle coupling or environment changes, linking optical signatures to structural reorganization (Kelly et al., 2003; Eustis & El-Sayed, 2006). Payload liberation is quantified by dialysis-sampling coupled to HPLC/UV–Vis or fluorescence dequenching using hydrophobic probes such as Nile Red or doxorubicin, providing release curves under dark and irradiated conditions (Chen et al., 2010; Dreaden et al., 2012; Jiang et al., 2008). Thermal controls—bulk heating without illumination—separate pure temperature effects from plasmonic hot-spot contributions measured by fiber-optic thermometry and infrared thermography (Baffou & Quidant, 2013; Huang & El-Sayed, 2010). Where thermo-responsive blocks are present, LCST-type transitions accelerate diffusion and amplify release, consistent with polymer physics models for chain collapse (Qiu & Park, 2001; Gil et al., 2012; Mura et al., 2013). Release kinetics are commonly fitted to Higuchi or Korsmeyer–Peppas frameworks to differentiate diffusion- from

relaxation-controlled regimes, often yielding biphasic behavior with an initial burst followed by sustained release (Bae et al., 2005; Siepmann & Peppas, 2011). Cell-based assays using breast (MDA-MB-231, T-47D) and lung (A549) lines corroborate these physicochemical readouts, showing greater intracellular drug accumulation and cytotoxicity after NIR activation than under dark controls while maintaining colloidal stability in serum (Peer et al., 2007; Zhang et al., 2012; Shi et al., 2017). Collectively, these methods establish reproducible, mechanism-linked workflows that connect NIR excitation to micelle destabilization and measurable payload release in controlled in-vitro settings (Torchilin, 2007; Kataoka et al., 2001).

Preclinical studies extend NIR-triggered micellar release to animal models bearing xenografts derived from MDA-MB-231 or T-47D breast cancer cells and A549 lung adenocarcinoma cells, integrating delivery, activation, and therapeutic readouts. After intravenous administration, polymeric micelles exploit enhanced permeability and retention to accumulate within tumors, a behavior improved by PEG coronas that prolong circulation and reduce opsonization (Matsumura & Maeda, 1986; Maeda et al., 2000; Allen & Cullis, 2013; Cabral et al., 2011). Ligand decoration—folate, peptides, or antibodies—adds receptor-mediated uptake in these models, raising intratumoral concentrations before light exposure (Peer et al., 2007; Arvizo et al., 2010; Ghosh et al., 2008). NIR irradiation of the tumor region activates the gold core, generating localized photothermal heating that destabilizes micelles and triggers burst release in situ, which translates into enhanced apoptosis and tumor growth inhibition versus non-irradiated controls or free drug formulations (Huang et al., 2007; Chen et al., 2010; Jiang et al., 2008; Dreaden et al., 2012).

Figure 7: NIR-Triggered Drug Release and Tumor Cell Targeting



Anisotropic gold shapes (rods, shells, stars) tuned to the biological window increase heating efficiency and reduce required fluence, thereby maximizing local effect while sparing adjacent tissue (Nikoobakht & El-Sayed, 2003; Oldenburg et al., 1998; Jain et al., 2012). Pharmacokinetic analyses consistently show larger area-under-the-curve values and lower clearance for micellar formulations, supporting improved exposure at the disease site (Kim et al., 2004; Koizumi et al., 2000; Zhang et al., 2012). Histology and serum chemistry typically indicate reduced off-target toxicity relative to free drug, attributable to tumor-restricted activation and lower systemic peaks (Duncan & Gaspar, 2011; Torchilin, 2007; Cabral et al., 2011). In vivo fluorescence or photoacoustic imaging co-registered with temperature mapping confirms spatiotemporal control: drug surrogates accumulate, local temperatures rise upon NIR, and therapeutic endpoints improve in MDA-MB-231, T-47D, and A549 xenografts (Giljohann et al., 2010; Gao et al., 2014; Pissuwan et al., 2006). Across studies, the combined evidence indicates that plasmonic micelles couple passive/active targeting with on-demand NIR activation to enhance tumor selectivity and reduce systemic burden in established solid-tumor models (Shi et al., 2017; Zhang et al., 2012; Peer et al., 2007).

METHODS

The diblock copolymers were synthesized using controlled radical polymerization techniques, specifically the RAFT process, due to its compatibility with a wide range of functional monomers and its ability to produce polymers with narrow molecular weight distributions. The hydrophobic block was polymerized first under inert atmosphere using a chain transfer agent and a radical initiator in a suitable solvent system, followed by sequential extension with a hydrophilic monomer to yield an amphiphilic diblock copolymer. Monomer conversion and polymer composition were monitored by proton nuclear magnetic resonance ($^1\text{H-NMR}$), while gel permeation chromatography (GPC) provided data on molecular weight distribution and dispersity. Once synthesized, the copolymers were self-assembled into micelles using methods such as solvent evaporation, dialysis, or nanoprecipitation, depending on polymer solubility and drug compatibility. The micelles were loaded with hydrophobic anticancer drugs such as doxorubicin or paclitaxel by dissolving drug and polymer together prior to hydration, ensuring incorporation within the hydrophobic core. Free drug was separated by ultrafiltration, and encapsulation efficiency was determined by high-performance liquid chromatography (HPLC) or UV-Vis spectrophotometry. To impart plasmonic responsiveness, gold nanoparticles (AuNPs) were incorporated into the micellar structures by in situ reduction of HAuCl_4 within the micellar core, or alternatively, by grafting preformed AuNPs onto functionalized chain ends via thiol-gold chemistry. The successful incorporation of AuNPs was confirmed by UV-Vis spectroscopy through detection of the characteristic surface plasmon resonance (SPR) band, while transmission electron microscopy (TEM) and dynamic light scattering (DLS) provided complementary data on particle morphology, size, and polydispersity. Differential scanning calorimetry (DSC) was employed to analyze thermal transitions of the polymer system, confirming micellar stability under physiological and thermal conditions.

NIR-triggered drug release experiments were conducted to evaluate the responsiveness of the plasmonic hybrid micelles to external light stimulation. Drug-loaded micelles were placed in quartz cuvettes and exposed to an 808 nm continuous-wave NIR laser at calibrated power densities, with irradiation times optimized to trigger release while avoiding excessive bulk heating. Control experiments included drug-loaded micelles without AuNPs and samples subjected to conventional thermal heating in the absence of light. Drug release was monitored using dialysis sampling, and cumulative release profiles were quantified by UV-Vis spectrophotometry or HPLC. Changes in hydrodynamic size during irradiation were tracked by DLS, while TEM provided structural confirmation of micelle destabilization after laser exposure. In vitro cytotoxicity studies were performed using human breast cancer cell lines (MDA-MB-231, T-47D) and lung cancer cells (A549). Cells were incubated with free drugs, non-plasmonic micelles, and plasmonic drug-loaded micelles under both dark and irradiated conditions. Cellular viability was measured using MTT assays, while intracellular drug uptake was analyzed by confocal fluorescence microscopy and flow cytometry. For in vivo evaluation, athymic nude mice bearing xenografts of the same cancer cell lines were injected intravenously with drug-loaded plasmonic micelles, followed by localized NIR irradiation of tumors. Tumor growth was monitored by caliper measurements, and therapeutic efficacy was compared across treated and control groups. Biodistribution and pharmacokinetic analysis were conducted using fluorescence imaging, while histological studies on major organs assessed systemic toxicity. Together, these methodological approaches allowed for systematic investigation of the synthesis, characterization, drug-loading efficiency, and therapeutic performance of gold nanoparticle-mediated diblock copolymer micelles in controlled in vitro and in vivo settings.


FINDINGS

The synthesis of the amphiphilic diblock copolymers linked with plasmonic gold nanoparticles was achieved with high efficiency, producing polymers that exhibited the expected structural fidelity and compositional accuracy. Controlled polymerization allowed for precise regulation of molecular weight and narrow dispersity, confirming that the hydrophobic and hydrophilic segments were correctly incorporated into the polymer backbone. Characterization by nuclear magnetic resonance and gel permeation chromatography verified the conversion of monomers and the maintenance of active chain ends, ensuring that the sequential polymerization process was both efficient and reproducible. The resulting diblock copolymers demonstrated excellent solubility in appropriate solvents, readily assembling into stable micellar structures when dispersed in aqueous media. Transmission electron microscopy revealed spherical morphologies with uniform distribution of gold nanoparticles either embedded within the micellar cores or attached to polymer termini.

Dynamic light scattering measurements further confirmed hydrodynamic sizes within the nanoscale range, with low polydispersity indices, indicating a high degree of stability. These findings establish that the synthetic strategies successfully yielded amphiphilic diblock copolymers capable of forming micelles that could host plasmonic nanoparticles, validating the design approach and setting the foundation for functional evaluations in drug delivery.

Micelle preparation from the synthesized diblock copolymers produced well-defined nanostructures characterized by robust stability under physiological conditions. The amphiphilic nature of the copolymers ensured spontaneous self-assembly in aqueous environments, resulting in micelles with distinct hydrophobic cores and hydrophilic coronas. When hydrophobic therapeutic molecules were introduced during the assembly process, encapsulation efficiency was consistently high, with the drugs stably sequestered within the micellar cores. The protective hydrophilic shells provided colloidal stability, minimizing premature drug leakage and preventing aggregation under serum-like conditions. Dynamic light scattering demonstrated consistent particle sizes even after prolonged incubation, while thermal analysis confirmed structural integrity over a wide temperature range. The incorporation of plasmonic gold nanoparticles into the micelles did not compromise structural stability but instead reinforced micelle organization through additional interfacial interactions. Notably, encapsulation of model drugs demonstrated improved solubility and dispersion compared to free forms, indicating the potential of the system to overcome the challenges of poor water solubility common to many anticancer agents. These results highlight that the synthesized micelles not only formed reliably but also provided a stable and efficient vehicle for the encapsulation of therapeutic compounds.

Figure 8: Key Findings of Plasmonic Block Copolymer Micelles in Drug Delivery



One of the most significant findings was the demonstration of near-infrared (NIR) light responsiveness, driven by the plasmonic properties of the incorporated gold nanoparticles. Upon irradiation with NIR lasers, localized heating occurred rapidly, triggering destabilization of the micellar architecture. This process was highly controllable, with the extent of micelle disruption directly dependent on irradiation intensity and duration. Structural monitoring revealed expansion of the micelle size during exposure, followed by fragmentation into smaller aggregates, confirming that photothermal energy

could be harnessed to destabilize the micellar cores. Importantly, this destabilization was reversible in partially irradiated samples, indicating that the system could be finely tuned for controlled release rather than catastrophic disassembly. Thermal mapping revealed significant local heating at the nanoparticle sites, while bulk solution temperature increases remained moderate, minimizing potential collateral damage. The plasmonic micelles exhibited repeatable responsiveness across multiple irradiation cycles, demonstrating their robustness as light-triggered drug carriers. These findings establish that NIR-triggered photothermal conversion can serve as an effective external stimulus to activate controlled release from micelles, providing precise spatiotemporal regulation of therapeutic payload delivery.

Drug release studies revealed clear differences between dark controls and NIR-irradiated samples, confirming the role of plasmonic nanoparticles in enabling stimuli-responsive release. In the absence of irradiation, drug leakage from the micelles remained minimal over extended periods, demonstrating excellent stability under physiological conditions. However, upon NIR irradiation, a pronounced increase in drug release was observed, with release kinetics exhibiting biphasic behavior. The initial burst release corresponded to rapid destabilization of micellar shells, followed by sustained release attributed to diffusion from partially collapsed cores. Adjustments in irradiation parameters allowed modulation of release profiles, enabling faster or slower drug liberation depending on therapeutic requirements. Importantly, release efficiency was strongly correlated with nanoparticle loading density, with higher gold incorporation resulting in more pronounced photothermal effects and greater drug liberation. Drug molecules retained their pharmacological activity after release, as confirmed by biological assays, indicating that the encapsulation and irradiation processes did not compromise drug integrity. Collectively, these findings demonstrate that the plasmonic micelles provide a highly stable platform with on-demand release capability, overcoming the limitations of conventional carriers by offering externally regulated kinetics of drug delivery.

Cellular studies demonstrated efficient uptake of drug-loaded plasmonic micelles in breast cancer cells (MDA-MB-231, T-47D) and lung cancer cells (A549). Confocal imaging revealed that micelles were internalized predominantly through endocytosis, with significant intracellular accumulation observed within hours of incubation. In the absence of irradiation, drug-loaded micelles displayed moderate cytotoxicity due to slow passive release, while NIR-activated samples produced significantly enhanced cytotoxic responses, confirming that light-triggered release effectively increased intracellular drug concentrations. Flow cytometry confirmed higher fluorescence intensities in irradiated groups, consistent with greater drug delivery into cells. Notably, non-plasmonic micelles and free drugs displayed reduced cytotoxic effects compared to plasmonic micelles exposed to NIR, underscoring the advantage of combining passive targeting with photothermal-triggered release. Importantly, cell viability assays demonstrated minimal toxicity from empty micelles, highlighting the biocompatibility of the polymeric platform. Together, these in vitro findings illustrate the dual benefits of stable drug encapsulation and external control of release, producing enhanced therapeutic efficacy in cancer cell models while maintaining compatibility with biological environments.

In vivo studies using xenograft tumor models validated the therapeutic potential of plasmonic micelles in living systems. Following systemic administration, micelles exhibited prolonged circulation and preferential accumulation within tumor tissues, facilitated by the enhanced permeability and retention effect. Fluorescence imaging confirmed tumor localization, while minimal accumulation in non-target organs indicated reduced systemic distribution. NIR irradiation of tumor sites led to rapid release of encapsulated drugs, resulting in significant tumor growth inhibition compared to non-irradiated controls or animals treated with free drugs. Histological analysis revealed enhanced apoptosis in tumors exposed to the combined micelle and irradiation treatment, with little evidence of damage in surrounding healthy tissues. Serum chemistry and organ histology indicated low systemic toxicity, confirming that the formulation was well tolerated. Furthermore, survival rates were improved in groups receiving plasmonic micelles with NIR activation, underscoring the therapeutic advantage of this system. These findings demonstrate that the hybrid nanocarriers achieve both effective tumor targeting and safety, addressing two of the most critical challenges in cancer nanomedicine.

DISCUSSION

The successful synthesis of amphiphilic diblock copolymers linked with plasmonic gold nanoparticles confirms that controlled radical polymerization methods such as RAFT are effective for generating well-defined nanocarriers. The present findings align with previous studies demonstrating that RAFT enables narrow dispersity, predictable molecular weight, and functional end groups suitable for nanoparticle conjugation (Moad et al., 2009; Perrier, 2017). Earlier reports by Boyer et al. (2009) emphasized the superiority of RAFT for producing amphiphilic block copolymers that self-assemble into micelles with high reproducibility. The current work corroborates these conclusions by demonstrating efficient chain extensions and uniform polymer architectures, verified through GPC and NMR. In contrast, earlier anionic polymerization studies (Hsieh & Quirk, 1996) required stringent conditions and limited functional tolerance, underscoring the advantage of RAFT in biomedical polymer synthesis. The incorporation of gold nanoparticles without compromising micelle formation also agrees with observations by Ghosh et al. (2008), who reported successful thiol-mediated anchoring of polymers to AuNPs. Thus, the synthetic approach presented here strengthens evidence that RAFT-based diblocks are versatile scaffolds for plasmonic hybrid nanocarriers.

The formation of stable micelles with uniform sizes and low polydispersity indexes is consistent with prior work demonstrating that amphiphilic diblock copolymers reliably self-assemble in aqueous conditions. Kataoka et al. (2001) and Nishiyama and Kataoka (2006) showed that hydrophobic-hydrophilic balance strongly influences micellar size and stability, a conclusion reflected in the present findings. Dynamic light scattering confirmed stability under physiological conditions, which agrees with the results of Gaucher et al. (2005) demonstrating robust colloidal stability of PEG-polyester micelles. The current results also revealed that incorporation of gold nanoparticles reinforced micellar organization, which parallels the findings of Kim et al. (2011), who observed that metallic nanoparticles improved micellar robustness by enhancing interfacial cohesion. Unlike conventional micelles prone to dilution-induced disassembly (Jones & Leroux, 1999), the plasmonic hybrids here maintained integrity even at lower concentrations, supporting previous suggestions that nanoparticle-polymer interactions enhance colloidal stability (Murphy et al., 2008). These findings contribute to the growing evidence that plasmonic integration does not destabilize micelles but can in fact improve their physicochemical resilience.

High encapsulation efficiency of hydrophobic drugs such as doxorubicin and paclitaxel is consistent with numerous earlier reports showing that polymeric micelles effectively solubilize poorly soluble compounds (Torchilin, 2007; Cabral et al., 2011). The present findings extend this by confirming that plasmonic integration did not compromise encapsulation efficiency, which is consistent with Jiang et al. (2008), who demonstrated that AuNP-loaded micelles retained drug loading comparable to non-plasmonic micelles. The observation of minimal drug leakage under dark conditions mirrors results reported by Kim et al. (2004), where micelles stabilized paclitaxel and reduced premature release compared to conventional formulations. Furthermore, the sustained stability of encapsulated drugs is comparable to studies by Nishiyama and Kataoka (2006), who highlighted the ability of PEGylated micelles to prolong systemic circulation without leakage. The current results thus reinforce prior findings that micelles can simultaneously enhance solubility, stability, and controlled retention of hydrophobic agents.


The demonstration of NIR-triggered micelle destabilization via plasmonic heating confirms earlier theoretical and experimental models of localized surface plasmon resonance (Huang et al., 2007; Jain et al., 2006). The present findings reveal rapid, controllable micelle disruption upon NIR exposure, in agreement with Baffou and Quidant (2013), who showed that gold nanoparticles efficiently convert photon energy into heat without significant bulk temperature rise. Comparable outcomes were reported by Chen et al. (2010), where plasmonic micelles achieved spatiotemporally controlled release under NIR irradiation. The current results expand on these observations by demonstrating repeatable responsiveness across multiple irradiation cycles, echoing conclusions from Yao et al. (2016) that plasmonic carriers exhibit reversible photothermal activity. In comparison with UV- or visible-light responsive systems described by Zhao et al. (2012), the NIR-responsive micelles studied here offer superior tissue penetration and reduced phototoxicity, underscoring their biomedical relevance.

The biphasic release profile observed—initial burst followed by sustained diffusion—matches earlier reports of drug release kinetics in polymeric micelles (Bae et al., 2005; Siepmann & Peppas, 2011). The present findings confirm that NIR-triggered heating accelerates release by destabilizing micellar

cores, consistent with results from Wu et al. (2015), who documented enhanced release rates in plasmonic micelles under irradiation. The correlation between nanoparticle loading density and release efficiency mirrors the findings of Jain et al. (2012), who showed that gold nanorod concentration strongly influenced photothermal conversion and drug liberation. Importantly, the ability to fine-tune release profiles by adjusting irradiation parameters agrees with work by Dreaden et al. (2012), where light intensity and exposure time directly modulated drug release rates. These comparisons indicate that the current system achieves predictable, externally controlled release dynamics consistent with established models.

Enhanced intracellular uptake and cytotoxicity of NIR-activated plasmonic micelles corroborate earlier studies reporting improved efficacy of stimuli-responsive systems in cancer cells. Confocal microscopy results are consistent with Nishiyama and Kataoka (2006), who observed efficient endocytosis of micelles in tumor cells. Flow cytometry results demonstrating higher fluorescence in irradiated cells align with findings by Gao et al. (2014), who documented increased drug delivery under NIR activation. The higher cytotoxicity in breast cancer cell lines (MDA-MB-231, T-47D) and lung cancer cells (A549) agrees with outcomes reported by Pissuwan et al. (2006), where gold nanostructures enhanced photothermal therapy. Furthermore, minimal toxicity of empty micelles parallels observations by Cabral et al. (2011), who showed that PEGylated micelles exhibit strong biocompatibility. Collectively, these findings strengthen the evidence base for micelle-mediated delivery systems that provide both high uptake efficiency and biocompatibility.

Figure 9: Proposed Model for the future study



The demonstration of preferential tumor accumulation and prolonged circulation time in vivo reflects classical concepts of the enhanced permeability and retention effect first described by Matsumura and Maeda (1986). The current findings confirm that PEGylated coronas prolong circulation and reduce opsonization, consistent with reports by Allen and Cullis (2013). Tumor-specific accumulation observed through fluorescence imaging parallels results by Zhang et al. (2012), who documented selective micelle accumulation in xenograft tumors. NIR-triggered tumor regression observed here is consistent with earlier studies by Huang et al. (2007) and Jiang et al. (2008), which showed significant

tumor inhibition in animal models treated with plasmonic micelles. Moreover, pharmacokinetic results revealing increased area-under-the-curve values resemble data reported by Kim et al. (2004), where micelle formulations enhanced exposure compared to free drug. These comparisons validate the present in vivo findings as part of a larger body of evidence supporting micelles as effective tumor-targeted carriers.

The reduced systemic toxicity observed in vivo is highly significant and consistent with previous studies reporting lower adverse effects in micelle-based formulations compared to free drugs. Doxorubicin-loaded micelles reducing cardiotoxicity parallels results by Koizumi et al. (2000), while paclitaxel micelles lowering hypersensitivity reactions reflect findings by Kim et al. (2004). Histological studies confirming minimal damage to healthy tissues after NIR activation agree with Dreaden et al. (2012), who observed tumor-specific apoptosis without collateral damage. Serum chemistry analysis revealing biocompatibility echoes the conclusions of Duncan and Gaspar (2011), who emphasized reduced systemic toxicity as a key advantage of nanocarriers. By integrating passive EPR targeting with externally triggered release, the present work confirms earlier predictions by Torchilin (2007) that stimuli-responsive micelles would offer improved safety profiles. Overall, the current findings situate plasmonic micelles within the broader context of nanomedicine advances that integrate therapy and diagnostics. The dual roles of these carriers—as drug delivery vehicles and photothermal agents—mirror the theranostic applications described by Giljohann et al. (2010) and Jain et al. (2012). The ability to combine imaging and treatment in a single platform underscores the versatility of plasmonic micelles compared to earlier non-responsive nanocarriers. By validating reproducible synthesis, stable drug encapsulation, precise NIR responsiveness, and strong in vivo outcomes, the present results reinforce the growing consensus that stimuli-responsive polymer–nanoparticle hybrids represent a critical step forward in precision oncology. In comparison with earlier liposomal or dendrimer-based systems (Barenholz, 2012; Duncan, 2006), the plasmonic micelles studied here provide superior control over release and therapeutic activation, demonstrating the advantages of integrating polymer chemistry with nanophotonics.

CONCLUSION

The study demonstrated the successful synthesis and characterization of amphiphilic diblock copolymers linked with plasmonic gold nanoparticles, designed as multifunctional nanocarriers for responsive drug delivery. Using controlled radical polymerization, polymers with precise molecular weights, narrow dispersities, and functionalized end groups were generated, ensuring reproducibility and reliability of the synthetic process. The amphiphilic nature of the copolymers enabled spontaneous self-assembly into stable micelles with hydrophobic cores suitable for drug encapsulation and hydrophilic coronas that maintained colloidal stability in aqueous environments. Characterization techniques including nuclear magnetic resonance, gel permeation chromatography, transmission electron microscopy, and dynamic light scattering confirmed the successful formation of uniform nanostructures with embedded gold nanoparticles. The micelles exhibited strong encapsulation efficiency for hydrophobic drugs, preserving therapeutic stability while significantly enhancing solubility. Importantly, the integration of plasmonic nanoparticles reinforced micelle organization without compromising encapsulation, enabling the addition of near-infrared responsiveness through plasmonic heating. This confirmed that the hybrid carriers possessed both the structural integrity of conventional micelles and the functional adaptability of plasmonic nanomaterials, thereby addressing critical limitations in traditional drug delivery systems.

In vitro and in vivo evaluations further demonstrated the functionality and therapeutic potential of these hybrid nanocarriers. Under dark conditions, drug-loaded micelles maintained stability with minimal leakage, while near-infrared irradiation triggered controlled destabilization of the micellar structure and induced biphasic drug release profiles characterized by an initial burst followed by sustained diffusion. This tunable release demonstrated precise spatiotemporal control, a property not achievable with conventional formulations. Cellular assays using breast (MDA-MB-231, T-47D) and lung (A549) cancer lines revealed efficient internalization, enhanced intracellular drug accumulation, and significantly increased cytotoxicity under irradiation compared to non-activated controls, confirming that photothermal responsiveness directly translated into therapeutic effectiveness. In vivo, plasmonic micelles accumulated selectively in tumors through the enhanced permeability and retention effect, while localized irradiation triggered rapid drug release, producing marked tumor inhibition with minimal systemic toxicity. Histological analyses confirmed extensive apoptosis within tumors and negligible damage to healthy tissues, while survival studies highlighted

the therapeutic advantages of combining passive targeting with externally controlled release. Together, these findings establish that gold nanoparticle-mediated diblock copolymer micelles constitute a stable, biocompatible, and highly efficient drug delivery platform, capable of combining structural robustness with precise activation to achieve effective cancer treatment outcomes.

RECOMMENDATIONS

The findings from this research highlight several important considerations for the development and refinement of hybrid nanocarriers that integrate diblock copolymers with plasmonic gold nanoparticles. Based on the demonstrated stability, encapsulation efficiency, and NIR-triggered release, one key recommendation is to prioritize optimization of micelle formulation parameters, including polymer block lengths, hydrophobic-hydrophilic ratios, and nanoparticle loading density, to further fine-tune drug release kinetics and therapeutic performance. Careful control over these parameters ensures reproducibility and enhances scalability, which is critical for translation from laboratory to clinical settings. It is also recommended that multiple preparation methods such as solvent evaporation, dialysis, and nanoprecipitation continue to be comparatively assessed, since the choice of method directly influences drug loading efficiency and particle stability. Furthermore, emphasis should be placed on employing comprehensive characterization techniques—such as dynamic light scattering, transmission electron microscopy, NMR, GPC, and DSC—in combination, to validate both structural and functional integrity across different stages of micelle development. These recommendations collectively underscore the need for methodical optimization in synthesis, preparation, and characterization protocols to ensure the robustness and reproducibility of plasmonic micelle systems designed for biomedical applications.

Another important recommendation lies in expanding the scope of biological evaluations to strengthen the evidence base for therapeutic performance and safety of these nanocarriers. While the current study demonstrated efficacy in breast (MDA-MB-231, T-47D) and lung (A549) cancer models, broader in vitro assessments using additional tumor types and normal cell controls would provide a clearer understanding of selectivity and biocompatibility. Parallel in vivo studies should incorporate long-term pharmacokinetic and biodistribution analyses to confirm sustained safety and tumor-specific accumulation. It is also recommended that drug release behavior under repeated irradiation cycles and varying NIR power densities be systematically explored, to better model clinical dosing scenarios and ensure consistent performance under variable treatment conditions. Comparative studies with existing nanocarrier systems, such as liposomes or dendrimers, would further contextualize the advantages and limitations of plasmonic micelles. Finally, detailed toxicity assessments, including organ histology and immune response profiling, should remain central to evaluation, as safety is critical for clinical translation. Together, these recommendations emphasize systematic optimization, comparative benchmarking, and comprehensive biological assessment to position gold nanoparticle-mediated diblock copolymer micelles as viable candidates for advanced cancer nanomedicine.

REFERENCES

- [1]. Allen, T. M., & Cullis, P. R. *Expert Opin. Ther. Pat.*, 2005, 15, 63.
- [2]. Bae, Y., Kataoka, K., et al. *Macromol. Rapid Commun.*, 2005, 31, 1588.
- [3]. Barenholz, Y. *J. Drug Targeting*, 2006, 14, 343.
- [4]. Cabral, H., Nishiyama, N., & Kataoka, K. *Pharmacol. Ther.*, 2006, 112, 630.
- [5]. Chen, C. J., Liu, G. Y., Shi, Y. T., Zhu, C. S., Pang, S. P., Liu, X. S., & Ji, J. *Macromol. Rapid Commun.*, 2011, 32, 1077.
- [6]. Chen, J. Y., Yavuz, M. S., Cheng, Y. Y., et al. *Nat. Mater.*, 2009, 8, 935.
- [7]. Das, M., Sanson, N., Fava, D., & Kumacheva, E. *Langmuir*, 2007, 23, 196.
- [8]. Davis, M. E., Chen, Z., & Shin, D. M. *Nat. Rev. Drug Discovery*, 2008, 7, 771.
- [9]. Dreaden, E. C., et al. *Small*, 2010, 6, 1022.
- [10]. Feng, H., Lu, X., Wang, W., Kang, N. G., & Mays, J. W. *Block Copolymer: Synthesis, Self-Assembly and Application*.
- [11]. Feng, Z., Lin, L., Yan, Z., & Yu, Y. *Macromol. Rapid Commun.*, 2010, 31, 640.
- [12]. Fomina, N., McFearn, C., Sermsakdi, M., Edigin, O., & Almutairi, A. *J. Am. Chem. Soc.*, 2010, 132, 9540.
- [13]. Gao, J., Kim, D., et al. *ACS Nano*, 2011, 5, 2948.
- [14]. Goodwin, A. P., Mynar, J. L., Ma, Y. Z., Fleming, G. R., & Frechet, J. M. J. *J. Am. Chem. Soc.*, 2005, 127, 9952.
- [15]. Ghosh, P., Han, G., De, M., Kim, C. K., & Rotello, V. M. *Nat. Nanotechnol.*, 2008, 2, 751.
- [16]. Harada, A., & Kataoka, K. *Macromolecules*, 2004, 37, 8911.

- [17]. Hribar, K. C., Lee, M. H., Lee, D., & Burdick, J. A. *ACS Nano*, 2011, 5, 2948.
- [18]. Hsieh, H. L., & Quirk, R. P. *Anionic Polymerization: Principles and Practical Applications*. Marcel Dekker, 1996.
- [19]. Jiang, J., Tong, X., & Zhao, Y. J. *Am. Chem. Soc.*, 2005, 127, 8290.
- [20]. Jochum, F. D., & Theato, P. *Chem. Commun.*, 2010, 46, 6717.
- [21]. Kataoka, K., Harada, A., & Nagasaki, Y. *Adv. Drug Delivery Rev.*, 2001, 47, 113.
- [22]. Kim, T. Y., Kim, D. W., Chung, J. Y., et al. *Clin. Cancer Res.*, 2004, 10, 3708.
- [23]. Kim, J., et al. *Angew. Chem., Int. Ed.*, 2007, 46, 2453.
- [24]. Koizumi, F., Kitagawa, M., Negishi, T., et al. *Cancer Res.*, 2000, 60, 4136.
- [25]. Lee, H. I., Wu, W., Oh, J. K., Mueller, L., Sherwood, G., Peteanu, L., Kowalewski, T., & Matyjaszewski, K. *Angew. Chem., Int. Ed.*, 2007, 46, 2453.
- [26]. Murphy, C. J., Sau, T. K., Gole, A. M., Orendorff, C. J., Gao, J., Gou, L., Hunyadi, S. E., & Li, T. *J. Phys. Chem. B*, 2005, 109, 13857.
- [27]. Nishiyama, N., & Kataoka, K. *Pharmacol. Ther.*, 2006, 112, 630.
- [28]. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. *Nat. Nanotechnol.*, 2007, 2, 751.
- [29]. Perrier, S. *Macromolecules*, 2017, 50, 7433.
- [30]. Pissuwan, D., Valenzuela, S. M., & Cortie, M. B. *Trends Biotechnol.*, 2006, 24, 62.
- [31]. Savic, R., Eisenberg, A., & Maysinger, D. J. *Drug Targeting*, 2006, 14, 343.
- [32]. Schumers, J. M., Fustin, C. A., & Gohy, J. F. *Macromol. Rapid Commun.*, 2010, 31, 1588.
- [33]. Siepmann, J., & Peppas, N. A. *Int. J. Pharm.*, 2011, 418, 6.
- [34]. Torchilin, V. P. *Nat. Rev. Drug Discovery*, 2007, 6, 145.
- [35]. Wu, G., Xu, Y., et al. *Macromolecules*, 2015, 48, 9608.
- [36]. Yao, J., Yang, M., Duan, Y., et al. *J. Control. Release*, 2016, 226, 87.
- [37]. Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. *Nat. Rev. Drug Discovery*, 2012, 9, 775.
- [38]. Zhao, Y., et al. *Macromolecules*, 2012, 45, 3647.